Neoplasms (Cancer)

Subscribe to Selected New Research on Neoplasms

383573 relevant articles (18324 outcomes, 47711 trials/studies) found for this Disease

Description: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Also Known As:

Cancer; Tumor; Tumors; Cancers; Neoplasm; Benign Neoplasm; Benign Neoplasms; Neoplasms, Benign; Neoplasm, Benign

Relationship Network

Disease Context: Research Results

Neoplasms: 383573

Cysts: 11369

Second Primary Neoplasms: 616

Hamartoma: 551

Paraneoplastic Syndromes: 357

Neoplastic Processes: 162

Precancerous Conditions: 161

Experimental Neoplasms: 46

Tumor Virus Infections: 34

Radiation-Induced Neoplasms: 33

Hereditary Neoplastic Syndromes: 20

Multiple Primary Neoplasms: 16

Hormone-Dependent Neoplasms: 13

Neoplasms by Histologic Type: 1

Neoplasms by Site: 1

Neoplastic Pregnancy Complications

Post-Traumatic Neoplasms

Related Diseases

1.	Neoplasms (Cancer)
2.	Neoplasm Metastasis (Metastasis)
3.	Carcinoma (Carcinomatosis)
4.	Pain (Aches)
5.	Breast Neoplasms (Breast Cancer)
2469 Diseases and 157781 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Experts

1.	Tokuda, Harukuni: 41 articles (02/2008 - 02/2002)
2.	Supuran, Claudiu T: 38 articles (06/2008 - 03/2003)
3.	Nishino, Hoyoku: 38 articles (01/2008 - 01/2002)
4.	Scozzafava, Andrea: 36 articles (04/2008 - 03/2003)
5.	Itoh, K: 35 articles (12/2007 - 02/2000)
6.	Bingham, Sheila: 32 articles (05/2008 - 08/2003)
7.	Rosenberg, Steven A: 31 articles (04/2008 - 03/2002)
8.	Riboli, Elio: 31 articles (05/2008 - 08/2003)
9.	Khaw, Kay-Tee: 31 articles (05/2008 - 05/2004)
10.	Trichopoulou, Antonia: 31 articles (05/2008 - 08/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Neoplasms:

1.	AntigensIBA 02/01/1987 - "In our own studies two types of approaches were also effective with the highly metastatic mouse tumor line ESb which carries a weak tumor associated antigen" 06/01/2007 - "The Ab/SA conjugate yielding the best tumor uptake and tumor-to-normal organ ratios of radioactivity varied depending on the target antigen expression on the cell line used, with 1F5/SA and Lym-1/SA yielding the most promising results overall" 01/01/2006 - "For this reason, DC-based immunization has been shown to be highly effective in eliciting CTL responses to viruses and tumor-associated antigens" 06/15/2004 - "The results show that the targeting of antigen to DCs in this way is highly effective at inducing immunity and protection against the tumor, with protection being at least partially dependent on the eosinophil chemokine eotaxin." 01/01/1978 - "It was found that most patients show an impaired immunobiological response, manifested in higher percentage of positive results with RHDT performed with the tumor antigen, and the reaction of microprecipitation with tumor and embryonal antigens, more week RFC and RBT" Get all the results and reference details, order at left...
2.	Cisplatin (Platino)FDA LinkGeneric 08/01/2001 - "The technical and radiobiological improvements in the science of radiotherapy, coupled with the use of cisplatin-containing regimens concurrent with radiation therapy, have improved dramatically the cure rate and quality of Life for cervical cancer survivors" 04/01/1999 - "Stressed cells, however, become hypersensitive to cisplatin, one of the most effective drugs against solid tumors, suggesting that preferential cytotoxicity to stressed cells may be important for the clinical efficacy against solid tumors" 01/06/1998 - "cis-Diamminedichloroplatinum(II) (cis-DDP or cisplatin) is a widely used anticancer drug that is most effective against tumors of the testis" 07/01/1996 - "Moreover, hMSH2 is overexpressed in testicular and ovarian tissue; tumors in these tissues are most effectively treated by cisplatin" 07/01/1993 - "IA cisplatin had remarkable therapeutic efficacy on the foot tumor as compared with IV cisplatin" Get all the results and reference details, order at left...
3.	DNA (Deoxyribonucleic Acid)IBA 10/20/2003 - "DNA minor groove binders (MGBs) are a class of anticancer agents highly effective in a variety of human cancers" 10/01/2001 - "CONCLUSION: The technique using CK-gating markedly improved the SPF measurement in DNA diploid tumors" 10/01/1999 - "Although illudins did not demonstrate significant activity as antiproliferative agents in tumor-bearing animals, several properties including its potent inhibition of DNA synthesis and a unique interaction with DNA led to a structure-activity-based synthetic effort to obtain analogs with improved therapeutic potential" 05/01/1997 - "Among the 27 patients with mesopharyngeal cancer, HPV DNA-positive patients experienced a higher incidence of complete remission than HPV DNA-negative patients (87.5% vs. 26.3%, p < 0.05)." 12/01/1996 - "In order to confirm the tumor specificity of these alterations, DNA samples obtained at complete remission were also analyzed in the three patients harboring an flt3 duplication, but no abnormal PCR product other than germline was detected in any of the samples" Get all the results and reference details, order at left...
4.	Doxorubicin (Adriamycin)FDA LinkGeneric 03/15/2006 - "Doxorubicin (DOX) is a highly effective treatment for several forms of cancer" 02/01/2006 - "Doxorubicin (DOX) is a highly effective treatment for several forms of cancer" 08/20/1997 - "BACKGROUND: Although doxorubicin remains one of the most effective agents for the treatment of solid tumors, there is an intensive effort to synthesize doxorubicin analogues (compounds with similar chemical structures) that may have improved antitumor properties" 08/01/1982 - "Doxorubicin hydrochloride is a chemotherapeutic agent highly effective against a wide range of neoplasms" 03/01/1978 - "Both compounds were highly effective against experimental mouse tumors at doses about ten times lower than those effective for adriamycin" Get all the results and reference details, order at left...
5.	Interleukin-2 (IL2)IBA 07/01/2005 - "Local interleukin 2 therapy is most effective against cancer when injected intratumourally." 11/20/1997 - "However, in a short-term therapy model, continued IL-2 expression was most effective against 3-day established tumors" 03/23/1994 - "Because IL-2 does not have a direct effect on cancer cells but rather mediates its antitumor activity by altering host immune reactions, these data represent the best available evidence that immunologic therapy for cancer can be effective in selected patients." 04/07/1993 - "CONCLUSION: Our results suggest that induction of anti-tumor immune response by local IL-2 production is most effective when the helper cytokine is secreted by the tumor cell" 01/01/1993 - "On the other hand, several groups have shown that application of intratumoral low doses of IL-2 can be highly effective against cancer and without toxic side-effects" Get all the results and reference details, order at left...
6.	Fluorouracil (Carac)FDA LinkGeneric 04/01/2004 - "Combined treatment with 5-FU and AxE1AdB-UPRT dramatically reduced the disseminated tumor burden without causing toxicity in normal tissues" 06/30/2000 - "Effective treatment of certain cancers with 5-fluorouracil (5-FU) and irradiation is well established; however, the most effective combination of these agents remains controversial" 09/01/1999 - "DPD activity is highly variable in cancer populations, and this variation may influence the antitumor efficacy of 5-fluorouracil" 01/01/1993 - "Local control improved as measured by increased frequency of tumor shrinkage and decreased frequency of primary tumor growth, recognizing the limitations of a pilot study and comparisons to best historical results achieved with standard short 5-fluorouracil schedules and radiotherapy" 09/01/1987 - "To date, HDFA + 5-FU is one of the most effective treatments for large bowel cancer." Get all the results and reference details, order at left...
7.	HormonesIBA 07/01/2005 - "Our in vitro results show that salicylhydrazides are highly potent compounds effective in both hormone receptor-positive and -negative cancer cells" 11/01/2002 - "Whilst opinion remains divided on the best treatment for localized disease, intervention for metastatic, hormone-independent cancer remains extremely limited" 02/01/1984 - "PSN research has yielded best results through the examination of those hormones produced by the tumor, esp" 09/28/2008 - "Lactone moiety-containing molecules may form the structural basis for the development of potent drugs effective against hormone-dependent cancers." 01/01/1981 - "However, response rates related to previous therapy and to important prognostic variables such as age of the patient, disease-free interval and hormone receptor content of the tumor tissue are poorly elucidated" Get all the results and reference details, order at left...
8.	Paclitaxel (Taxol)FDA LinkGeneric 07/01/2008 - "In particular, sagopilone is highly effective in reducing the growth of paclitaxel-resistant cancer cells" 01/01/2008 - "The development of paclitaxel resistance in tumors is one of the most significant obstacles to successful therapy" 05/15/2006 - "The development of paclitaxel-resistance in tumors is one of the most significant obstacles to successful therapy" 04/01/2005 - "The development of resistance to paclitaxel in tumors is one of the most significant obstacles to successful therapy" 05/15/2002 - "Paclitaxel, an antimicrotubule agent, is highly efficacious in the treatment of adult tumors and is in clinical evaluation in childhood tumors" Get all the results and reference details, order at left...
9.	AntibodiesIBA 07/01/2008 - "Importantly, most studies of EPO-R detection in tumor tissue have provided falsely positive results because of the lack of EPO-R specific antibodies" 06/01/1991 - "2) In an animal model on tumor localization and biodistribution studies, CEA-specific antibodies obtained more highly tumor targeting and cleared more rapidly from the blood and non-tumor organs than CEA-nonspecific antibodies did, so that tumor to nontumor ratios was increased" 08/07/2006 - "A murine subrenal capsule fresh human tumor explant assay was utilized to test efficacy of various murine monoclonal anti-HER2 antibodies, and the data were helpful in choosing the most efficacious for subsequent human engineering for clinical use" 09/01/2005 - "The generation of human or human-like mAbs has led to the recent development of therapeutic antibodies that are potentially highly beneficial in the treatment of cancer" 12/01/1996 - "RESULTS: The two broadest spectrum antibodies (AE1/AE3, E3/C4) showed overall the best results with immunohistochemical staining, being positive in over 95% of tumors" Get all the results and reference details, order at left...
10.	Estrogens (Estrogen)FDA Link 01/01/1988 - "The features that most influenced prognosis within the categories defined by site of first relapse were disease-free interval (less than 24 months v greater than or equal to 24 months), and estrogen receptor content in the primary tumor" 10/01/1987 - "Because of its very high affinity and unusual dissociation kinetics, [3H]11 beta-CME2 should be a very useful ligand for studies of estrogen receptor dynamics and in the assay of estrogen receptor concentrations in tumors and tissues." 01/01/2004 - "In particular, we found a marked decrease in the number of apoptotic cells and debris after estrogen + irradiation, as compared to irradiation alone, only in younger patients and TNM 1+2 tumors" 01/01/1980 - "Jensen (1978) and Knight et al (1977) observed that patients with no or very low estrogen-receptor content in their tumors have a shorter disease-free interval" 10/01/1994 - "PATIENTS AND METHODS: One hundred sixty-seven good-risk patients with an estrogen receptor (ER+) positive recurrence or, in case of unknown receptor status, a disease-free interval (DFI) of greater than 12 months and < or = three recurrent tumor nodules each < or = 3 cm in diameter were entered onto the study" Get all the results and reference details, order at left...
17011 Drugs and Important Bio-Agents and 318690 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 04/01/1991 - "These results suggest that chemotherapy can be administered during pregnancy, even during the first trimester, because it is not hazardous to the fetus; nevertheless, this study is inadequate in size to exclude the possibility of teratogenesis, and more reports are necessary to define the best treatment from cancer during pregnancy." 11/01/1990 - "From maturing data in retrospective reviews, preliminary data from prospective trials, and recent well-conducted animal studies, chemotherapy and hormonal deprivation appear most effective when tumor volumes are the smallest" 01/01/2008 - "Large clinical trial networks and development of systematic research in clinical practice settings, such as that featured by the National Cancer Institute for cancer chemotherapy, would greatly accelerate the progress in incorporating new, as well as existing, agents into the best treatment strategies" 01/01/2008 - "The best results were reported in patients who had had cytoreductive surgery for primary tumor, radiofrequency ablation and chemotherapy (42)" 01/01/2008 - "These "guided molecular missiles" provide bright prospects for the development of highly efficacious new generation drugs for cancer chemotherapy." Get all the results and reference details, order at left...
2.	Immunotherapy 09/01/2005 - "This study shows that DC maturation with cytokine cocktails different from those most commonly used could be beneficial for immunotherapy trials in cancer patients." 01/01/2004 - "DC-based immunotherapy has shown early promise in clinical cancer trials, and efforts are being made to determine the optimal method of delivery of cells to achieve the best outcome" 09/01/2008 - "Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours?" 07/01/2005 - "Advanced disease states, rapidly growing tumors, and accrual of patients with extremely short survival are factors that have been identified to limit the efficacy of allogeneic immunotherapy" 07/01/2005 - "The efficacy of intravesical BCG remains the most successful example of cancer immunotherapy to date." Get all the results and reference details, order at left...
3.	Heterologous Transplantation (Xenotransplantation) 06/24/2008 - "Most strikingly, in developed HER2-overexpressing tumor xenograft model, administration of PE-NPs-HER (0.9 mg/kg) showed a much better therapeutic efficacy in inhibiting tumor growth compared with PE-HER and other controls: final mean tumor load was 13+/-6 mm(3) (mean+/-SD; n=8, significantly smaller than all other groups by ANOVA at 95% confidence interval)" 06/12/2008 - "Moreover, taxoid 19 exhibited excellent in vivo efficacy against highly drug-resistant CFPAC-1 pancreatic as well as DLD-1 human colon tumor xenografts in mice." 01/01/2008 - "While the induction of IRP1 did not affect cell proliferation in culture, it dramatically reduced the capacity of the cells to form solid tumor xenografts in nude mice" 01/08/2007 - "Among these PAK1-blocking approaches, the PP1/GL-2003 combination is the most effective in the therapy of this cancer xenograft model" 04/01/2004 - "Considering the enormous effort that has taken place over the years to discover new chemotherapeutic drugs for treating the common cancers, the conventional murine and xenograft test systems used to test efficacy for drug development have identified only a limited number of useful agents that are active clinically at well tolerated doses" Get all the results and reference details, order at left...
4.	Aftercare (After-Treatment) 07/01/2006 - "Pregnancy rates and pregnancy outcomes particularly regarding in term delivery is the best after treatment of early stages of cervical cancer using proposed protocol, while very promising results are published in studies with radical vaginal trachelectomy as well" 09/01/2005 - "No significant differences were found for subsites after treatment, although patients with mobile tongue tumors showed the best results" 06/01/2005 - "CONCLUSION: Most recurrences occurred after a long disease-free interval after treatment and often outside the initial tumor site" 01/01/2003 - "The best candidate for surgery had no evidence of additional metastatic disease, good performance status, and a long disease-free interval after treatment of the primary tumor" 02/01/2002 - "Long-term survival after treatment for childhood cancers has dramatically improved in the past 25 years" Get all the results and reference details, order at left...
5.	Combination Drug Therapy (Combination Chemotherapy) 07/01/2005 - "Most institutes participated in nonrandomized trials designed to evaluate the safety and efficacy of combination chemotherapy, surgery, and radiotherapy in each group study and treated children with these tumors The results are reviewed and areas for future investigation are identified." 11/01/2004 - "The best results were achieved in patients with pT2A tumor invasion depth, G1 differentiation of tumor cells after TUR with adjuvant polychemotherapy (PCT) recurrences in these patients arose by 41.2% less frequently than in patients after TUR only, 5-year survival in patients after TUR+PCT was 83.3%" 01/01/1990 - "The polychemotherapy followed by the radiotherapy should be preferably applied to patients with tumors of the disease group A, because in this group the best results were obtained with an average survival time of 21.3 months, a remission length of 13.4 months, an improvement of life quality for 12.5 months and a high remission rate" 03/01/1989 - "The stage of disease at the time of the original procedure greatly influences the results, and, as would be anticipated, the results are infinitely better in those patients who have a second-look operation after Stage I cancer has been diagnosed than in patients who have a second-look procedure after an initial staging of Stage III. The best results will be achieved in those patients who have had very aggressive surgery at the initial procedure--followed by combination chemotherapy for approximately six to nine months.(ABSTRACT TRUNCATED AT 250 WORDS)" 09/28/2006 - "The overall combination chemotherapy response rate and the complete remission rate were significantly higher among patients with mutant p53 tumors than those with wild-type p53 tumors (35/42 (83%) vs. 32/58 (55%); P=0.003 and 18/42 (43%) vs. 16/58 (28%); P=0.03, respectively)" Get all the results and reference details, order at left...
692 Therapies and Procedures and 109617 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Patient-Physician Research Summary Report on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 18324 Outcomes
Top 200 Key Medications
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF for "Psoriasis" >>

Price:

$24.00 & Delivery via PDF download,
updates for 1 year

Proceed to Checkout >>

Research Interface Subscription

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Searches
2 clicks from Disease to Drug to Evidence
Trial references
All the Positive Outcomes
Drug and Therapy searches
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface Subscription

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>